Clinical Trials Directory

Trials / Completed

CompletedNCT00143845

Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant

Phase II Trial of Adjuvant Cellular Immunotherapy for High-Risk Hematologic Malignancy After Reduced Intensity Allogeneic Stem Cell Transplantation

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
54 (actual)
Sponsor
University of Michigan Rogel Cancer Center · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether a reduced intensity conditioning regimen for stem cell transplant with donor cells will allow the donor cells to be effective without causing health problems.

Detailed description

In this research study patients will receive dosages of chemotherapy that are lower than the usual dosages. The study will determine whether a shorter duration of immunosuppression will permit the donor cells to be effective against the cancer without causing more severe GVHD (Graft Versus Host Disease). Also to be determined is whether the patient's cancer can be prevented from relapsing after blood stem cell transplant by using prophylactic treatment, giving a donor leukocyte infusion BEFORE a relapse happens. In this research study samples of blood and bone marrow will be analyzed. These samples will be examined to study the cellular production of inflammatory cytokine levels in attempt to be able to predict which patients will have complications like GVHD or relapse.

Conditions

Interventions

TypeNameDescription
PROCEDUREReduced intensity conditioningBusulfan and Fludarabine regimen
PROCEDURERapid immunosuppressive taperTaper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
PROCEDUREProphylactic donor leukocyte infusionsIf the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.

Timeline

Start date
2003-04-01
Primary completion
2010-11-01
Completion
2013-02-01
First posted
2005-09-02
Last updated
2017-03-08
Results posted
2014-06-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00143845. Inclusion in this directory is not an endorsement.